For Healthcare Professionals

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

clipboard-pencil

About the study

The purpose of this study is to evaluate the safety, tolerability, and dose regimen of daratumumab when administered in combination with various treatment regimens for the treatment of multiple myeloma.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Confirmed diagnosis of symptomatic multiple myeloma and measurable secretory disease
  2. For carfilzomib-lenalidomide-dexamethasone (KRd) regimen: newly diagnosed myeloma. For carfilzomib-dexamethasone (CFZ-dex) regimen: relapsed or refractory disease
  3. Eastern Cooperative Oncology Group performance status score of 0, 1, or 2
  4. Pretreatment clinical laboratory values must meet protocol-defined parameters during the screening phase

EXCLUSION CRITERIA

  1. Previously received daratumumab or other anti-CD38 therapies
  2. Diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions
  3. Peripheral neuropathy or neuropathic pain Grade 2 or higher
  4. Prior or concurrent invasive malignancy (other than multiple myeloma) within 5 years of study start
  5. Exhibiting clinical signs of meningeal involvement of multiple myeloma
  6. Known chronic obstructive pulmonary disease, persistent asthma, or a history of asthma within 2 years
  7. Seropositive for human immunodeficiency virus, hepatitis B, or hepatitis C
  8. Any concurrent medical or psychiatric condition or disease that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study
  9. Clinically significant cardiac disease
  10. Plasma cell leukemia or POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Email iconEmail Study Center

Study’s details


Contition

Multiple Myeloma

Age

18+

Phase

Phase 1

Participants needed

242

Est. Completion Date

Mar 2023

Treatment type

Interventional


Sponsor

Janssen Research & Development, LLC

ClinicalTrials.gov identifier

NCT01998971

Study number

54767414MMY1001

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.